SEC Form 4 · accession 0001859453-26-000008
Vera Therapeutics, Inc. · VERA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Marshall Fordyce
Officer — PRESIDENT AND CEO · Director
Period of report
Jun 23, 2026
Accepted (ET)
Jun 24, 2026 · 4:55 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001831828
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF2 | Jun 23, 2026 | S | 18,412 | $37.9311 | D | 198,332 | D | |
| Class A Common Stock | Jun 23, 2026 | S | 88 | $38.43 | D | 198,244 | D | |
| Class A Common Stock | holding | — | — | — | 122,949 | I | By GRAT | |
| Class A Common Stock | holding | — | — | — | 99,081 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F2The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.43 to $38.315, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.